Lateral habenula astroglia modulate the potentiating antidepressant-like effects of bright light stimulation in intractable depression.
Sarah Delcourte, Amel Bouloufa, Renaud Rovera, Elie Brunet, Hiep D Le, April E Williams, Satchidananda Panda, Rihab Azmani, Olivier Raineteau, Ouria Dkhissi-Benyahya, Nasser Haddjeri
Frontiers in Pharmacology 2025 DOI: 10.3389/fphar.2025.1592909 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal model study Peer reviewed |
|---|---|
| Population | Mice |
| Intervention | Bright light stimulation |
| Topics | Depression Ketamine |
| Keywords | Animal model Bright light stimulation Chemogenetic Refractory depression Rods Depression treatment Light therapy Neuroscience research Antidepressant medication |
| Citations | 3 |
| Key points | Bright light stimulation potentiates the effect of antidepressants in a mouse model of refractory depression via a circuit involving rods, lateral habenula astroglia, and serotonin. |
Abstract
Beside image vision, light plays a pivotal role in regulating diverse non-visual functions, including affective behaviors. Recently, bright light stimulation (BLS) was revealed to be beneficial for treating non-seasonal depression, although its mechanism of action is not fully understood. We developed a novel mouse model of refractory depression, induced through social isolation and chronic despair during the active (dark) phase of the animal, and we have tested if antidepressant treatments, including BLS, could protect against anxio-depressive-like behavior. We report that anxiety- and depressive-like behaviors are resistant to BLS as well as to both conventional and new antidepressants, including ketamine. Remarkably, we unveil that BLS potentiates the effect of antidepressants, and this beneficial effect is mediated via rod retinal photoreceptors. Furthermore, we demonstrate that both chemogenetic activation of lateral habenula (LHb) astroglia and serotonin (5-HT) depletion prevent the potentiating effect of BLS on chronic despair. These results reveal, for the first time, that BLS enhances the efficacy of antidepressants through an unexpectedly circuit involving rods, LHb astroglia and 5-HT.
Comparable studies
Other preclinical and animal studies on ketamine for depression, most cited first.
Citations in the library
Cites 6
- Psychedelics promote plasticity by directly binding to BDNF receptor TrkB Nature Neuroscience June 1, 2023
- Brain region-specific action of ketamine as a rapid antidepressant. Science August 9, 2024
- Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player? Neuropsychopharmacology March 1, 2024
- Prefrontal cortex molecular clock modulates development of depression-like phenotype and rapid antidepressant response in mice. Nature Communications August 23, 2024
- Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB/cJ mice. Neuropharmacology January 2017
and 1 more in the library